Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-6
(
IL-6
) release from purified blood monocytes was determined in patients with breast cancer or prostatic cancer before and after radiation treatment (Rx). Plasma levels of
IL-6
and neopterin were also determined. Spontaneous
IL-6
release in vitro was higher in breast than in prostatic cancer or in controls. Strong lipopolysaccharide (LPS)-induced cellular
IL-6
release was detected in breast cancer and controls but was subnormal in prostatic cancer. Addition of indomethacin to cultures had no effect on
IL-6
release. Rx generally increased levels of in vitro released
IL-6
and raised LPS-stimulated
IL-6
secretion in prostatic cancer to normal. Plasma levels of
IL-6
were lower in breast than in prostatic cancer or controls. Rx resulted in a tendency towards raised levels in both patient groups suggestive of monocyte activation. In accordance with this, plasma levels of neopterin, which were normal before treatment, increased in prostatic cancer patients after Rx. Taken together, the results of this study indicate that monocyte release as well as plasma levels of
IL-6
are affected by the
malignant state
as well as by radiation treatment. In view of the antiproliferative effects of
IL-6
, the findings may have bearing on the pathogenesis and treatment of malignant disease.
...
PMID:Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. 145 47
Chronic inflammation plays a role in transformation from normal cell to
malignant state
.
Interleukin-6
(
IL-6
) regulates inflammation and various physiological processes.
IL-6
promoter polymorphism (-174G>C) is associated with transcription differences in vitro and in vivo. High expression of
IL-6
may result in oxidative DNA damage and enhance risk of carcinogenesis. Therefore, we aimed to evaluate association of
IL-6
-174G>C polymorphism with predisposition to esophageal cancer (EC) in 369 subjects (168 patients with EC and 201 controls). We observed significant association of
IL-6
-174C non-carrier genotype with risk of EC, (OR=2.29; P=0.001), with squamous cell carcinoma (SCC) histology (OR=2.26; P=0.001) and tumor at upper and lower anatomical locations (OR=5.97; P=0.009 and OR=2.34; P=0.034). Patients having
IL-6
-174C non-carrier genotype were at elevated risk of metastasis (OR=2.49; P=0.005). In conclusion,
IL-6
-174G>C gene polymorphism may confer high risk for EC and its clinical characteristics.
...
PMID:Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. 1850 91
